[Long-term follow-up after drug-eluting stents for patients with ST-segment elevation myocardial infarction: a single center study].
To evaluate the long-term efficacy and safety of DES in the setting of primary PCI in our single center. From September 2004 to November 2008, 464 patients undergoing primary PCI for STEMI were included at the 28th Division in Beijing Anzhen Hospital. The adverse events were compared among different types of DES. The major adverse cardiac events [MACE, including sudden cardiac death, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization (TVR), reinfarction and coronary artery bypass graft], all-cause death, major bleeding, anti-platelet therapy and secondary prevention of coronary heart disease of different types of DES were no significant differences. The cumulative incidence of MACE and stent thrombosis were 9.3% and 1.1% respectively, different types of DES were 9.4%, 5.1%, 5.9%, 6.6% (P = 0.483) and 3.1%, 0.0%, 0.0%, 0.0% (P = 0.092) respectively. The patients in the DES group had longer duration of dual antiplatelet therapy (average 16.2 ± 6.7 months). No major bleeding occurred in all patients with the long-term and low-dose aspirin (100 mg). Different types of DES have the same results in the setting of primary PCI, and were long-term safe and effective with a reasonable strategy for anti-platelet therapy and secondary prevention.